Trials / Completed
CompletedNCT01324518
Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
Safety and Efficacy of ORM-12741 on Cognitive and Behavioral Symptoms in Patients With Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- All
- Age
- 55 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of Alzheimer's disease.
Detailed description
The purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of cognitive and behavioral symptoms in patients with Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ORM-12741 | 60mg twice a day |
| DRUG | ORM-12741 | 200mg twice a day |
| DRUG | Placebo for ORM-12741 | Placebo twice a day |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-09-01
- Completion
- 2012-10-01
- First posted
- 2011-03-29
- Last updated
- 2021-04-28
- Results posted
- 2021-04-28
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT01324518. Inclusion in this directory is not an endorsement.